A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment.

• Status: Not yet recruiting
• Trial end date: 2035-06-22

Summary

The primary objectives of the study are:

For Phase 1

• To find out if linvoseltamab is safe and well tolerated

• To find out what the most appropriate dosing schedule would be for future clinical trials

For Phase 2

•To find out if it works to treat multiple myeloma

The secondary objectives of the study are:

For Phase 1 and 2

• To find out how linvoseltamab moves throughout the body over time (pharmacokinetics)

• To find out how much B-cell maturation antigen (BCMA) participants have in their blood

• To find out if the participants' immune systems respond to linvoseltamab.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Regeneron Pharmaceuticals